MICROBIAL COMPOSITIONS AND METHODS OF USE FOR CANINE ENTEROPATHY AND DYSBIOSIS
The disclosure relates to isolated microorganisms-including novel strains of the microorganisms-microbial ensembles, and compositions comprising the same. Furthermore, the disclosure teaches methods of utilizing the described microorganisms, microbial compositions, and compositions comprising the same, in methods for treating or preventing gastrointestinal enteropathy or dysbiosis in canines. In particular aspects, the disclosure provides methods of treating or preventing morbidity and mortality caused by GI pathogenesis or autoimmunity.
1 . A composition comprising:
(a) at least one purified bacterium from Peptacetobacter hiranonis (also known as Clostridium hiranonis ); and
(b) at least one carrier.
2 . The composition of claim 1 , wherein the at least one purified bacterium comprises a 16S nucleic acid sequence that is at least 97% identical to a nucleic acid sequence of SEQ ID NO: 38 or SEQ ID NO: 165.
3 . The composition of claim 1 , wherein the at least one purified bacterium comprises a 16S nucleic acid sequence that is at least 98% identical to a nucleic acid sequence of SEQ ID NO: 38 or SEQ ID NO: 165.
4 . The composition of claim 1 , wherein the at least one purified bacterium comprises a 16S nucleic acid sequence that is at least 99% identical to a nucleic acid sequence of SEQ ID NO: 38 or SEQ ID NO: 165.
5 . The composition of claim 1 , wherein the at least one purified bacterium comprises a 16S nucleic acid sequence that is 100% identical to a nucleic acid sequence of SEQ ID NO: 38 or SEQ ID NO: 165.
6 . The composition of claim 1 , wherein the at least one purified bacterium comprises a 16S nucleic acid sequence that is at least 97% identical to a nucleic acid sequence of SEQ ID NO: 165.
7 . The composition of claim 1 , wherein the at least one purified bacterium comprises a 16S nucleic acid sequence that is at least 98% identical to a nucleic acid sequence of SEQ ID NO: 165.
8 . The composition of claim 1 , wherein the at least one purified bacterium comprises a 16S nucleic acid sequence that is at least 99% identical to a nucleic acid sequence of SEQ ID NO: 165.
9 . The composition of claim 1 , wherein the at least one purified bacterium comprises a 16S nucleic acid sequence that is 100% identical to a nucleic acid sequence of SEQ ID NO: 165.
10 . The composition of claim 9 , wherein the at least one purified bacterium comprises a 16S nucleic acid sequence that is at least 97% identical to a nucleic acid sequence selected from the group consisting of: SEQ ID NOs: 166-175.
11 . The composition of claim 9 , wherein the at least one purified bacterium comprises a 16S nucleic acid sequence that is at least 98% identical to a nucleic acid sequence selected from the group consisting of: SEQ ID NOs: 166-175.
12 . The composition of claim 9 , wherein the at least one purified bacterium comprises a 16S nucleic acid sequence that is at least 99% identical to a nucleic acid sequence selected from the group consisting of: SEQ ID NOs: 166-175.
13 . The composition of claim 9 , wherein the at least one purified bacterium comprises a 16S nucleic acid sequence that is 100% identical to a nucleic acid sequence selected from the group consisting of: SEQ ID NOs: 166-175.
14 . The composition of claim 9 , wherein the at least one purified bacterium comprises a 16S nucleic acid sequence that is at least 97% identical to a nucleic acid sequence of SEQ ID NO: 172.
15 . The composition of claim 9 , wherein the at least one purified bacterium comprises a 16S nucleic acid sequence that is at least 98% identical to a nucleic acid sequence of SEQ ID NO: 172.
16 . The composition of claim 9 , wherein the at least one purified bacterium comprises a 16S nucleic acid sequence that is at least 99% identical to a nucleic acid sequence of SEQ ID NO: 172.
17 . The composition of claim 9 , wherein the at least one purified bacterium comprises a 16S nucleic acid sequence that is 100% identical to a nucleic acid sequence of SEQ ID NO: 172.
18 . The composition of claim 1 , wherein the composition further comprises one or more bacteria comprising a 16S nucleic acid sequence that is at least 97% identical to a nucleic acid sequence selected from any one of SEQ ID NOs: 1-37, 39-164, and 176-333.
19 . The composition of claim 1 , wherein the at least one purified bacterium is lyophilized and/or spray-dried.
20 . The composition of claim 1 , wherein the at least one carrier is selected from the group consisting of: an edible feed grade material, an aluminosilicate-containing mineral, a zeolite, calcium carbonate, a prebiotic, and a flavoring agent.
21 . The composition of claim 1 , wherein the at least one purified bacterium is present in the composition at a concentration of at least 10 2 cells per gram of the composition.
22 . The composition of claim 1 , wherein the at least one purified bacterium is present in the composition as a whole cell or lysed cell.
23 . The composition of claim 1 , wherein the composition is formulated as a tablet, a pill, a capsule, a powder, a solution, a suspension, a food, or an emulsion.
24 . The composition of claim 1 , wherein the composition is formulated as a capsule.
25 . The composition of claim 1 , wherein the composition is mixed with or sprinkled on top of a food.
26 . The composition of claim 1 , wherein the composition is formulated as a dry food, a wet food, a kibble, or a raw food.
27 . A method of imparting at least one desirable trait in a canine, the method comprising administration of the composition of claim 1 to the canine.
28 . The method of claim 27 , wherein the at least one desirable trait is selected from the group consisting of: improved fecal consistency, increased regular bowel movements, reduced incidence of diarrhea, reduced incidence of constipation, less straining during defecation, reduced side-effects from antibiotics, improved dental health, brighter eyes, increased energy, increased appetite, improved fur and coat quality, decreased incidence of infectious or non-infectious disease, increased lifespan, and/or improved performance of the canine.
29 . A method of treating or preventing gastrointestinal dysbiosis or gastrointestinal enteropathy in a canine, the method comprising administration of the composition of claim 1 to the canine.
30 . A method of reducing side-effects from antibiotics in a canine, the method comprising administration of the composition of claim 1 to the canine.